Literature DB >> 21691329

Connective tissue diseases: Lupus nephritis-winning a few battles but not the war.

George K Bertsias, Dimitrios T Boumpas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21691329     DOI： 10.1038/nrrheum.2011.88

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full?

Authors:  Dimitrios T Boumpas; George K Bertsias; James E Balow
Journal:  Ann Rheum Dis       Date:  2010-12       Impact factor: 19.103

2.  Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006.

Authors:  Karen H Costenbader; Amrita Desai; Graciela S Alarcón; Linda T Hiraki; Tamara Shaykevich; M Alan Brookhart; Elena Massarotti; Bing Lu; Daniel H Solomon; Wolfgang C Winkelmayer
Journal:  Arthritis Rheum       Date:  2011-06

3.  End-stage renal disease due to lupus nephritis among children in the US, 1995-2006.

Authors:  Linda T Hiraki; Bing Lu; Steven R Alexander; Tamara Shaykevich; Graciela S Alarcón; Daniel H Solomon; Wolfgang C Winkelmayer; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2011-07

4.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

5.  Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995.

Authors:  M M Ward
Journal:  Arch Intern Med       Date:  2000-11-13

Review 6.  Confusion about the appropriate use of erythropoiesis-stimulating agents in patients undergoing maintenance dialysis.

Authors:  Wolfgang C Winkelmayer
Journal:  Semin Dial       Date:  2010 Sep-Oct       Impact factor: 3.455

7.  Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

Authors:  Gerald B Appel; Gabriel Contreras; Mary Anne Dooley; Ellen M Ginzler; David Isenberg; David Jayne; Lei-Shi Li; Eduardo Mysler; Jorge Sánchez-Guerrero; Neil Solomons; David Wofsy
Journal:  J Am Soc Nephrol       Date:  2009-04-15       Impact factor: 10.121

8.  The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide.

Authors:  F A Houssiau; C Vasconcelos; D D'Cruz; G D Sebastiani; E de Ramon Garrido; M G Danieli; D Abramovicz; D Blockmans; A Cauli; H Direskeneli; M Galeazzi; A Gül; Y Levy; P Petera; R Popovic; R Petrovic; R A Sinico; R Cattaneo; J Font; G Depresseux; J-P Cosyns; R Cervera
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

9.  EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.

Authors:  G Bertsias; J P A Ioannidis; J Boletis; S Bombardieri; R Cervera; C Dostal; J Font; I M Gilboe; F Houssiau; T Huizinga; D Isenberg; C G M Kallenberg; M Khamashta; J C Piette; M Schneider; J Smolen; G Sturfelt; A Tincani; R van Vollenhoven; C Gordon; D T Boumpas
Journal:  Ann Rheum Dis       Date:  2007-05-15       Impact factor: 19.103

10.  Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004.

Authors:  Michael M Ward
Journal:  J Rheumatol       Date:  2009-01       Impact factor: 4.666
  10 in total
  3 in total

1.  Chest imaging manifestations in lupus nephritis.

Authors:  Hui Qin; Qiang Guo; Nan Shen; Xinfang Huang; Huawei Wu; Minfang Zhang; Chunde Bao; Shunle Chen
Journal:  Clin Rheumatol       Date:  2014-04-03       Impact factor: 2.980

2.  Identify differential inflammatory cellular and serology pathways between children and adult patients in the lupus registry.

Authors:  Chung-Yuan Hsu; Wen-Chan Chiu; Yi-Ling Huang; Yu-Jih Su
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

3.  5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivative attenuates lupus nephritis with less effect to thymocyte development.

Authors:  Fengjiao Wei; Xiaoqing Zhou; Huanpeng Chen; Xuyan Tian; Zhonghua Liu; Bolan Yu; Xixin He; Chuan Bai; Zhaofeng Huang
Journal:  Immunol Res       Date:  2021-07-04       Impact factor: 2.829
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.